文献速递特殊人群用药治疗药物监测与药物基因组学

整合胎盘灌注数据与PBPK模型评估多替拉韦母婴暴露

Assessment of Maternal and Fetal Dolutegravir Exposure by Integrating Ex Vivo Placental Perfusion Data and Physiologically-Based Pharmacokinetic Modeling.
PubMed 文献 · Clin Pharmacol Ther · 2020-01-24

本研究将妊娠期PBPK模型与体外胎盘灌注获得的跨胎盘转运数据相结合,模拟多替拉韦(DTG)的母体及胎儿暴露。模型预测的妊娠晚期胎儿暴露与临床脐血数据一致,且50 mg每日一次给药下预测的胎儿谷浓度仍高于90%病毒抑制所需浓度,提示该整合方法可用于评估妊娠期DTG药代动力学。

要点

  • 妊娠晚期50 mg每日一次DTG的预测胎儿谷浓度高于90%病毒抑制浓度。
  • PBPK模型整合体外胎盘灌注数据可模拟胎儿DTG暴露。
  • 预测的胎儿暴露与临床脐血观察数据一致。

核心结论

  • 整合妊娠期PBPK模型与体外胎盘灌注跨胎盘转运数据可模拟DTG的母体及胎儿暴露,是评估妊娠期DTG药代动力学的有前景的方法。

研究设计与样本

  • 基于健康志愿者生理与DTG药代动力学数据建立妊娠期PBPK模型,并以体外双侧人绒毛膜板灌注实验获得的跨胎盘动力学数据扩展胎儿-胎盘单元。

主要发现

  • 妊娠晚期母体给药后模拟的胎儿暴露与临床观察的DTG脐血数据一致。
  • 50 mg每日一次给药下预测的胎儿谷浓度(Ctrough)仍高于90%病毒抑制所需浓度。

临床怎么用

  • 该整合建模方法可用于妊娠期DTG暴露评估,支持50 mg每日一次给药下胎儿暴露维持在有效浓度以上。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Antiretroviral therapy during pregnancy reduces the risk of vertical HIV-1 transmission. However, drug dosing is challenging as pharmacokinetics (PK) may be altered during pregnancy. We combined a pregnancy physiologically-based pharmacokinetic (PBPK) modeling approach with data on placental drug transfer to simulate maternal and fetal exposure to dolutegravir (DTG). First, a PBPK model for DTG exposure in healthy volunteers was established based on physiological and DTG PK data. Next, the model was extended with a fetoplacental unit using transplacental kinetics obtained by performing ex vivo dual-side human cotyledon perfusion experiments. Simulations of fetal exposure after maternal dosing in the third trimester were in accordance with clinically observed DTG cord blood data. Furthermore, the predicted fetal trough plasma concentration (Ctrough ) following 50 mg q.d. dosing remained above the concentration that results in 90% of viral inhibition. Our integrated approach enables simulation of maternal and fetal DTG exposure, illustrating this to be a promising way to assess DTG PK during pregnancy.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Freriksen JJM, Schalkwijk S, Colbers AP, et al. Assessment of Maternal and Fetal Dolutegravir Exposure by Integrating Ex Vivo Placental Perfusion Data and Physiologically-Based Pharmacokinetic Modeling. Clin Pharmacol Ther. 2020. PMID: 31868223. doi:10.1002/cpt.1748

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。